Fluidigm Corporation focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, the company develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide.